Literature DB >> 8625742

Long-term biochemical and virological response to natural interferon-alpha in patients with chronic hepatitis C.

H Hagiwara1, N Hayashi, A Kasahara, M Oshita, K Katayama, M Naito, M Masuzawa, H Yoshihara, Y Shimizu, H Fusamoto, T Kamada.   

Abstract

To determine the long-term response to interferon-alpha, 134 patients with chronic hepatitis C were followed for more than a year after therapy. Follow-up was stopped for 14 patients and 43 patients received retreatment. The remaining 77 patients were followed for 26-46 months, and 39 of them achieved long-term sustained alanine aminotransferase (ALT) normality. This normality was achieved in 35/38 short-term sustained responders, which was significantly higher (P < 0.001) than in the short-term relapsers (2/38) and the short-term nonresponders (2/44). Hepatitis C virus (HCV) RNA remained negative in 27 (73%) of 37 patients in the long-term sustained ALT normality group. However, only one (1.6%) of 63 long-term responders was negative for HCV RNA. The results of HCV RNA testing for the long-term period agreed with those at three to six months after therapy. Serum ALT levels during the first six months after therapy and HCV RNA testing at three to six months after therapy are important for predicting long-term sustained ALT normality and HCV RNA negativity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625742     DOI: 10.1007/bf02091544

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  34 in total

1.  Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients.

Authors:  Y Kanazawa; N Hayashi; E Mita; T Li; H Hagiwara; A Kasahara; H Fusamoto; T Kamada
Journal:  Hepatology       Date:  1994-11       Impact factor: 17.425

2.  A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

Authors:  S Brillanti; J Garson; M Foli; K Whitby; R Deaville; C Masci; M Miglioli; L Barbara
Journal:  Gastroenterology       Date:  1994-09       Impact factor: 22.682

3.  Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b.

Authors:  G Saracco; F Rosina; M L Abate; L Chiandussi; V Gallo; E Cerutti; A Di Napoli; A Solinas; A Deplano; A Tocco
Journal:  Hepatology       Date:  1993-12       Impact factor: 17.425

4.  Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response.

Authors:  L Pagliaro; A Craxí; C Cammaá; F Tiné; V Di Marco; O Lo Iacono; P Almasio
Journal:  Hepatology       Date:  1994-04       Impact factor: 17.425

5.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferon.

Authors:  P Marcellin; N Boyer; C Degott; M Martinot-Peignoux; V Duchatelle; E Giostra; J Areias; S Erlinger; J P Benhamou
Journal:  Liver       Date:  1994-12

7.  Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha.

Authors:  H Hagiwara; N Hayashi; E Mita; K Ueda; T Takehara; A Kasahara; H Fusamoto; T Kamada
Journal:  Hepatology       Date:  1992-01       Impact factor: 17.425

8.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

9.  Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon.

Authors:  M Shindo; A M Di Bisceglie; J H Hoofnagle
Journal:  Hepatology       Date:  1992-06       Impact factor: 17.425

10.  A pilot study of ribavirin therapy for chronic hepatitis C.

Authors:  A M Di Bisceglie; M Shindo; T L Fong; M W Fried; M G Swain; N V Bergasa; C A Axiotis; J G Waggoner; Y Park; J H Hoofnagle
Journal:  Hepatology       Date:  1992-09       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.